Investors bought shares of Heron Therapeutics Inc (NASDAQ:HRTX) on weakness during trading on Thursday. $25.48 million flowed into the stock on the tick-up and $7.64 million flowed out of the stock on the tick-down, for a money net flow of $17.84 million into the stock. Of all equities tracked, Heron Therapeutics had the 11th highest net in-flow for the day. Heron Therapeutics traded down ($0.48) for the day and closed at $26.79

A number of research firms recently weighed in on HRTX. Cantor Fitzgerald set a $50.00 price objective on shares of Heron Therapeutics and gave the stock a “buy” rating in a report on Friday, September 21st. BidaskClub cut shares of Heron Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, September 22nd. Zacks Investment Research cut shares of Heron Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, October 10th. ValuEngine raised shares of Heron Therapeutics from a “hold” rating to a “buy” rating in a research note on Tuesday, January 8th. Finally, Needham & Company LLC reissued a “buy” rating and set a $64.00 target price (down previously from $66.00) on shares of Heron Therapeutics in a research note on Wednesday. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and twelve have issued a buy rating to the stock. The company has an average rating of “Buy” and an average target price of $51.91.

The stock has a market cap of $2.08 billion, a price-to-earnings ratio of 7.34 and a beta of 1.49.

Heron Therapeutics (NASDAQ:HRTX) last posted its quarterly earnings data on Wednesday, November 7th. The biotechnology company reported ($0.49) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.44) by ($0.05). Heron Therapeutics had a negative net margin of 326.79% and a negative return on equity of 72.23%. The business had revenue of $19.79 million for the quarter, compared to the consensus estimate of $19.84 million. During the same quarter last year, the business posted ($0.77) EPS. The business’s revenue for the quarter was up 130.9% on a year-over-year basis. Analysts anticipate that Heron Therapeutics Inc will post -2.28 earnings per share for the current year.

Large investors have recently bought and sold shares of the company. Cubist Systematic Strategies LLC bought a new position in shares of Heron Therapeutics during the 2nd quarter valued at about $151,000. Jefferies Group LLC acquired a new position in shares of Heron Therapeutics in the third quarter worth about $202,000. Verition Fund Management LLC acquired a new position in shares of Heron Therapeutics in the third quarter worth about $208,000. Pacer Advisors Inc. acquired a new position in shares of Heron Therapeutics in the third quarter worth about $223,000. Finally, Public Employees Retirement Association of Colorado acquired a new position in shares of Heron Therapeutics in the third quarter worth about $224,000.

COPYRIGHT VIOLATION NOTICE: This report was posted by Watch List News and is the sole property of of Watch List News. If you are accessing this report on another website, it was illegally stolen and republished in violation of international copyright laws. The correct version of this report can be read at https://www.watchlistnews.com/traders-buy-heron-therapeutics-hrtx-on-weakness/2753564.html.

Heron Therapeutics Company Profile (NASDAQ:HRTX)

Heron Therapeutics, Inc, a biotechnology company, engages in developing medicines to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.

Featured Article: What is the Consumer Price Index (CPI)?

Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.